The global apoptosis assay market size is expected to reach USD 7.5 billion by 2027, expanding at a CAGR of 7.6%, according to a new report by Grand View Research, Inc. Extensive research activities on expanding applications of drug-induced apoptosis assays have propelled the inclination of pharmaceutical manufacturers towards incorporating cell cycle products in the drug discovery and designing process.
The
introduction of affordable and easy to perform kits that can be accommodated in
complex experiments is expected to minimize the overhead costs of apoptosis
experiments. Companies are providing highly precise reagents and lot-to-lot
reproducibility in sample measurements.
Professionals
at pharmaceutical companies are making use of cell-cycle inhibitors and
Apoptosis-Inducing Factors (AIF)/ molecules to explore possible drug targets.
Also, high demand for caspase activity assays along with Bcl-2 protein family
across pharmaceutical companies for apoptosis detection has been observed in
recent years. Biotechnology companies are enhancing quantification techniques
to enable real-time monitoring of apoptotic cellular dynamics.
The
presence of established guidelines and protocols for cell-potency assays has
strengthened the development of efficient cell-death detection assays. Whereas,
stringent regulations with respect to the approval of cell-potency assays are
ensuring successful uptake of market products launched.
The
flow cytometry segment dominated the market and accounted for the largest
revenue share in 2019. This is attributed to the increasing adoption of the
technique among researchers. It helps in finding the difference between intact
mitochondria (healthy cells) and permeabilized mitochondria (cells undergoing
death). The segment is anticipated to grow fast over the forecast period.
The
pharmaceutical and biotechnology segment dominated the market in 2019 and is
anticipated to continue its dominance over the forecast period. This is
attributed to the rising incidence of cancer and neurodegenerative disorders.
In addition, the growing significance of programmed cell death or apoptosis to
treat chronic diseases is driving the segment growth.
Full Research Report On Apoptosis Assay Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/apoptosis-market
Apoptosis Assay
Market Report Highlights
- The kits
segment dominated the market and accounted for a revenue share of around
50.0% owing to increasing investment by key market players
- Increase in
the demand for fluorochrome-labeled inhibitors of caspases has made
reagents the fastest growing product segment in the market
- Application
of these inhibitors with other techniques is anticipated to enhance the
apoptosis assessment, thereby driving segment growth
- Owing to the
wide adoption and easy availability of products, flow cytometry is
estimated to account for a substantial share of approximately 35.0% in
2019
- The
increasing significance of continuous monitoring of programmed cell death
across novel drug discoveries and development of advanced therapeutics is
set to propel market growth
- North America
has dominated the market in terms of revenue share in 2019, and Asia
Pacific is expected to witness the fastest growth in the coming years as a
result of the expanding CRO landscape in the region
- Key companies
are competing in terms of a combination of products and services in order
to maintain market share.
Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/apoptosis-market/request/rs1
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company, registered
in the State of California and headquartered in San Francisco. The company
provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment